In Vivo Selection of anti-glioblastoma DNA aptamer-drug conjugates in an orthotopic patient-derived xenograft model
Preprint
Abstract
Glioblastoma (GBM) is an aggressive, high-grade glioma with a near-universally fatal prognosis. Therapeutic failure is often attributed to the highly selective blood brain barrier (BBB), the diffuse infiltrative nature of the tumor, and the marked intratumoral heterogeneity of GBM. Although antibody drug conjugates ADCs have shown promise for high grade gliomas such as GBM, efficacy is limited by ADC size. Aptamers—short, synthetic, single-stranded DNA or RNA molecules—can be ∼6-fold lower in molecular weight than IgG antibodies and have the potential to cross the intact BBB. Unlike other nucleic acid-based therapies, aptamer function arises from three-dimensional shape rather than genetic coding. Here we aim to replace the targeting component of the ADC paradigm with a DNA aptamer, thus creating an aptamer-drug conjugate (ApDC). We employed in vivo SELEX using an orthotopic patient-derived xenograft (PDX) GBM mouse model and a vast (∼100 trillion 80-mer sequences) ApDC library. We report the results from this first in vivo ApDC selection of its kind. We characterize target tissue binding ex vivo , cell association, biodistribution, and pharmacokinetics from this selection. This study exemplifies an unbiased approach to a problem that rational design has yet to overcome, offering a new direction for GBM therapeutic development.Keywords
Funding Information
- National Institute of General Medical Sciences (T32GM145408)
- National Institute of General Medical Sciences (R35GM143949)
- National Institute of Neurological Disorders and Stroke (K99NS138490)
- National Institute of Neurological Disorders and Stroke (R61NS128071)
- National Cancer Institute (F30CA294722)
This publication has 39 references indexed in Scilit:
- Drug Delivery Strategies to Cross, Target, or Bypass the Blood–Brain BarrierMolecular Pharmaceutics, 2025
- Antibody-drug conjugates: Current challenges and innovative solutions for precision cancer therapyMed, 2025
- Homogeneity of antibody-drug conjugates critically impacts the therapeutic efficacy in brain tumorsCell Reports, 2022
- Optimized quantitative PCR analysis of random DNA aptamer librariesAnalytical Biochemistry, 2022
- Trends in glioblastoma: outcomes over time and type of intervention: a systematic evidence based analysisJournal of Neuro-Oncology, 2020
- AptaSUITE: A Full-Featured Bioinformatics Framework for the Comprehensive Analysis of Aptamers from HT-SELEX ExperimentsMolecular Therapy Nucleic Acids, 2018
- Antibody–drug conjugates in glioblastoma therapy: the right drugs to the right cellsNature Reviews Clinical Oncology, 2017
- Conjugate-SELEX: A High-throughput Screening of Thioaptamer-liposomal Nanoparticle Conjugates for Targeted Intracellular Delivery of Anticancer DrugsMolecular Therapy Nucleic Acids, 2016
- DNA Ligase-Mediated Translation of DNA Into Densely Functionalized Nucleic Acid PolymersJournal of the American Chemical Society, 2012
- Nuclease-resistant nucleic acid ligands to vascular permeability factor/vascular endothelial growth factorChemistry & Biology, 1995